Suzanne Holden, Vice President, Corporate Accounts & Country Leader United Kingdom at Thermo Fisher Scientific, shares her thoughts on why she is excited about the research and investment in predictive genomics. Read this short article that discusses: addressing unmet needs, improving patient outcomes; polygenic risk scores - stratifying the population and from drug discovery to clinical though validation: 'The future, now: Revolutionising disease prevention through predictive genomics'